Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

Journal of Infectious Diseases

Volumn 183, Issue 7, 2001, Pages 1121-1125

  Nagashima, Kirsten A ^a   Thompson, Daniah A D ^b   Rosenfield, Soraya I ^a   Maddon, Paul J ^a   Dragic, Tatjana ^b   Olson, William C ^a  

^a Clinical Research   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 IMMUNOGLOBULIN G2; ENFUVIRTIDE; UNCLASSIFIED DRUG; VIRUS ATTACHMENT INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CD4 IMMUNOADHESINS; CELL FUSION; CELL LINE; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EUKARYOTIC CELLS; HELA CELLS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 0035313589     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319284     Document Type: Article

References (15)

1. Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
2. Recombinant CD4-IgG2 in HIV-1 infected children: Phase 1/2 study
3. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
4. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual
5. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates
6. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
7. HIV entry and its inhibition
8. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
9. -cells is mediated by the chemokine receptor CC-CKR-5
10. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer
11. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
12. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
13. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120
14. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
15. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41